FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983115827> ?p ?o ?g. }

• W1983115827 endingPage "2132" @default.
• W1983115827 startingPage "2128" @default.
• W1983115827 abstract "Complement is a powerful host defense system that contributes to both innate and acquired immunity. There are three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathway. Each generates a C3 convertase, a serine protease that cleaves the central complement protein, C3. Nearly all the biological consequences of complement are dependent on the resulting cleavage products. Properdin is a positive regulator of complement activation that stabilizes the alternative pathway convertases (C3bBb). Properdin is composed of multiple identical protein subunits, with each subunit carrying a separate ligand-binding site. Previous reports suggest that properdin function depends on multiple interactions between its subunits with its ligands. In this study I used surface plasmon resonance assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin promotes the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also found that properdin binds to preformed alternative pathway C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or pre-formed C3bB and C3bBb complexes. New C3bP and C3bBP intermediates can lead to in situ assembly of C3bBbP. The full stabilizing effect of properdin on C3bBb would be attained as properdin binds more than one ligand at a time, forming a lattice of properdin: ligand interactions bound to a surface scaffold. Complement is a powerful host defense system that contributes to both innate and acquired immunity. There are three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathway. Each generates a C3 convertase, a serine protease that cleaves the central complement protein, C3. Nearly all the biological consequences of complement are dependent on the resulting cleavage products. Properdin is a positive regulator of complement activation that stabilizes the alternative pathway convertases (C3bBb). Properdin is composed of multiple identical protein subunits, with each subunit carrying a separate ligand-binding site. Previous reports suggest that properdin function depends on multiple interactions between its subunits with its ligands. In this study I used surface plasmon resonance assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin promotes the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also found that properdin binds to preformed alternative pathway C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or pre-formed C3bB and C3bBb complexes. New C3bP and C3bBP intermediates can lead to in situ assembly of C3bBbP. The full stabilizing effect of properdin on C3bBb would be attained as properdin binds more than one ligand at a time, forming a lattice of properdin: ligand interactions bound to a surface scaffold. The complement system contributes to both innate and acquired immunity (1Volanakis J.E. Cooper M.D. Koprowski H. Interface between Innate and Acquired Immunity. Springer-Verlag, Berlin2002: 41-56Google Scholar). Recent reports indicate that complement has additional biological roles, participating in tissue regeneration (2Mastellos D. Lambris J. Trends Immunol. 2002; 23: 485-491Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar) and in sperm: egg recognition (3Riley-Vargas R.C. Gill D.B. Kemper C. Liszewski M.K. Atkinson J.P. Trends Immunol. 2004; 25: 496-503Abstract Full Text Full Text PDF PubMed Scopus (150) Google Scholar). There are three pathways of complement activation (4Volanakis J.E. Volanakis J.E. Frank M.M. The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York1998: 9-32Crossref Google Scholar), the classical pathway (CP), 2The abbreviations used are: CP, classical pathway; LP, lectin pathway; AP, alternative pathway; DAF, decay acceleration factor; CR1, complement receptor 1; SPR, surface plasmon resonance; NHS, N-hydroxyl succinimide; EDC, ethyl diethylaminopropyl carbodiimide; RUs, resonance units; CR, complement receptor; MCP, membrane cofactor protein. lectin pathway (LP), and alternative pathway (AP). Although each pathway is induced by a different set of activators, all three pathways lead to the enzymatic cleavage of C3. That step is catalyzed by the C3 convertases. Two homologous C3 convertases occur, one generated by the AP and the other by the CP and LP. Both convertases are serine proteases that cleave C3 at a single site, generating C3a and C3b. Nascent C3b covalently binds to macromolecules, immune complexes, and cell surfaces, where it promotes immune adherence and phagocytosis or membrane lysis, and C3a directs proinflammatory and vasoactive reactions. The AP presents a unique role in the complement activation cascade. Because it is activated by C3b, its own product, it functions as a positive feedback loop, producing a rapid and vigorous local response. Through C3b, the AP also amplifies activation initially triggered by the CP and LP. The first step in the assembly of the alternative pathway C3 convertase is the association of factor B (a zymogen) with C3b in the presence of Mg2+ (4Volanakis J.E. Volanakis J.E. Frank M.M. The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York1998: 9-32Crossref Google Scholar). Once bound to C3b, factor B is cleaved by the serine protease factor D, producing the Ba and Bb fragments. Ba dissociates from the complex while Bb and the cation remain bound to C3b, forming the active AP C3 convertase, C3bBb. The C3 convertases are serine proteases that cleave only C3. Nascent C3b (C3b*) generated by convertase activity binds to a target surface or water molecule via reaction of its metastable thioester moiety. That reaction takes place within ∼60 μs of cleavage, and during that time C3b* can diffuse up to 30 nm before it becomes covalently bound to a target (5Sim R.B. Twose T.M. Paterson D.S. Sim E. Biochem. J. 1981; 193: 115-127Crossref PubMed Scopus (202) Google Scholar). C3b can also bind the C3 convertase, forming the C5 convertase, C3bBbC3b. C5 convertase activity leads to the formation of the membrane attack complex. The C3 convertases are deactivated upon spontaneous dissociation or by facilitated dissociation (decay acceleration) mediated by the regulators of complement activation proteins decay acceleration factor (DAF), complement receptor one (CR1), C4b-binding protein, and factor H (6Hourcade D. Holers V.M. Atkinson J.P. Adv. Immunol. 1989; 45: 381-416Crossref PubMed Scopus (380) Google Scholar, 7Liszewski M.K. Atkinson J.P. Volanakis J.E. Frank M.M. The Human Complement System in Health Disease. Marcel Dekker, Inc., New York1998: 149-166Google Scholar). Convertase assembly is suppressed by the proteolytic cleavage of C3b (and C4b) as mediated by factor I in the presence of membrane cofactor protein (MCP, CD46), C4b-binding protein, CR1, or factor H (6Hourcade D. Holers V.M. Atkinson J.P. Adv. Immunol. 1989; 45: 381-416Crossref PubMed Scopus (380) Google Scholar, 7Liszewski M.K. Atkinson J.P. Volanakis J.E. Frank M.M. The Human Complement System in Health Disease. Marcel Dekker, Inc., New York1998: 149-166Google Scholar). These negative control processes are essential for the protection of self-tissue from C-mediated damage and for the prevention of unregulated C3 turnover and depletion. Properdin is the only known naturally occurring positive regulator of complement activation (8Schwaeble W.J. Reid K.B. Immunol. Today. 1999; 20: 17-21Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar). Individuals deficient for properdin are prone to lethal pyogenic (especially neisserial) infections (9Braconier J.H. Sjoholm A.G. Soderstrom C. Scand. J. Infect. Dis. 1983; 15: 339-345Crossref PubMed Scopus (28) Google Scholar, 10Densen P. Weiler J.M. Griffiss J.M. Hoffmann L.G. N. Engl. J. Med. 1987; 316: 922-926Crossref PubMed Scopus (124) Google Scholar, 11Kolble K. Reid K.B. Int. Rev. Immunol. 1993; 10: 17-36Crossref PubMed Scopus (26) Google Scholar). Properdin increases the stability of the AP convertases 10-fold on target surfaces and immune complexes (12Fearon D.T. Austen K.F. J. Exp. Med. 1975; 142: 856-863Crossref PubMed Scopus (317) Google Scholar), and inhibits the factor H-mediated cleavage of C3b by factor I (13Medicus R.G. Gotze O. Muller-Eberhard H.J. J. Exp. Med. 1976; 144: 1076-1093Crossref PubMed Scopus (142) Google Scholar). We want to understand how properdin influences the AP convertase, and in particular how it directs AP activation to surface targets. Native properdin occurs in head-to-tail dimers, trimers, and tetramers in the fixed ratio of 22:52:28 (14Smith C.A. Pangburn M.K. Vogel C.W. Muller-Eberhard H.J. J. Biol. Chem. 1984; 259: 4582-4588Abstract Full Text PDF PubMed Google Scholar). The higher oligomers have greater C-regulatory activity (14Smith C.A. Pangburn M.K. Vogel C.W. Muller-Eberhard H.J. J. Biol. Chem. 1984; 259: 4582-4588Abstract Full Text PDF PubMed Google Scholar). Previously, Farries et al. (15Farries T.C. Lachmann P.J. Harrison R.A. Biochem. J. 1988; 252: 47-54Crossref PubMed Scopus (56) Google Scholar) showed that properdin has a greater affinity for cell-bound C3bB and cell-bound C3bBb than for cell-bound C3b. Moreover, they offered a model for properdin; convertase interactions based on the multivalent nature of properdin:ligand associations (15Farries T.C. Lachmann P.J. Harrison R.A. Biochem. J. 1988; 252: 47-54Crossref PubMed Scopus (56) Google Scholar). In this study, I used surface plasmon resonance-based assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin accelerates the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also observed that properdin binds preformed AP C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or preformed C3bB and C3bBb complexes. Further C3bBb is formed from the new C3bP and C3bBP intermediates. This model accounts for the capacity of properdin to direct C activation to surface targets. Surface Plasmon Resonance Analysis—Surface plasmon resonance (SPR) methodology provides a sensitive real time measure of protein: protein interactions (16Myszka D.G. Methods Enzymol. 2000; 323: 325-340Crossref PubMed Scopus (192) Google Scholar). SPR analysis was conducted with a BIAcore 2000 instrument and the manufacturer's software package (BIAcore, Piscataway, NJ). CM5 sensor chips (BIAcore catalog number BR-1000-14) were used throughout with Mg2+-HEPES running buffer (filtered and degassed 10 mm HEPES, 150 mm NaCl, 2 mm MgCl2, 0.005% Tween 20, pH 7.4). All experiments were carried out at 25 °C. Kinetic values were obtained using the manufacturer's software. BIAcore flow paths were activated with a fresh 1:1 mixture of 0.05 m N-hydroxyl succinimide and 0.2 m ethyl diethylaminopropyl carbodiimide injected at 5 ml/min for 7 min. Complement proteins were then covalently attached to the activated surface. Properdin, C3b, or iC3b (10 μg/ml in 10 mm citrate buffer, pH 4.8) was injected in the experimental flow path, at 10 μl/min for 3-7 min followed by 1 m ethanolamine, pH 8.5, at 5 μl/min for 7 min. A control flow path was produced as above but without protein in the buffer. Combinations of purified complement proteins in running buffer (or running buffer alone to observe protein dissociation) were injected at 30 μl/min for varying times. Output was expressed in resonance units (RUs). Changes in RUs, indicative of changes in mass bound to the biosensor surface, were expressed as the difference between the experimental and control flow paths. Because RUs are linear units, quantitation of ligand binding can be calculated directly from changes in RUs. Non-covalently bound protein was stripped from the properdin-coated surface with a 20-s pulse of 5 m NaCl. N-Hydroxyl succinimide, ethyl diethylaminopropyl carbodiimide, and ethanolamine solutions were purchased from BIAcore and stored at -20 °C. Proteins—Native human complement proteins (properdin, C3b, iC3b, factor B, Bb, factor H, and factor D) were obtained from Advanced Research Technologies, San Diego, CA. Soluble DAF, CPPs 2-4, which carries the active site of DAF, was a gift of Dr. Feng Lin of Case Western University. Impact of Properdin on the Association of Factor B with C3b-coated Biosensor Surfaces—The impact of properdin on C3bBb stability has long been appreciated (12Fearon D.T. Austen K.F. J. Exp. Med. 1975; 142: 856-863Crossref PubMed Scopus (317) Google Scholar). C3bBb has a half-life of ∼2-3 min at 37° C. Properdin extends that half-life 10-fold. Previous biochemical studies also suggest that properdin can promote C3b:B association (17DiScipio R.G. Biochem. J. 1981; 199: 485-486Crossref PubMed Scopus (82) Google Scholar). To explore this possibility further, we examined the association of factor B with surface-bound C3b in the presence or absence of properdin. Each SPR biosensor is composed of a series of up to four activated surfaces. Injected fluids flow over each surface in rapid succession. C3b was covalently attached to two flow path surfaces. Subsequently, properdin was bound to one of the two surfaces via non-covalent association with C3b. The properdin:C3b association was relatively stable (t1/2 of 23 min) and likely involved concomitant attachment of polyvalent properdin to multiple C3b ligands. The C3b-coated and the C3bP-coated surfaces were simultaneously treated with fluid phase factor B, and the generation of C3bB and C3bBbP was examined. As shown in Fig. 1, 5-fold more C3bBP than C3bB accumulated during the treatment period. These results suggest that C3bP could be an important intermediate in the formation of AP convertases. Interactions of AP Proteins with a Properdin-coated Biosensor Surface—I next used SPR to investigate the monovalent binding of properdin to C3b, C3bB, and C3bBb (Fig. 2A). Properdin was covalently attached to a biosensor surface and treated with a succession of protein mixtures in Mg2+-HEPES buffer for 60 s followed by Mg2+-HEPES buffer alone. The biosensor was injected with C3b, factor B, Bb, or factor D. Small amounts of C3b (less than 10 RUs) bound the properdin-coated surface. No factor B, Bb, or factor D binding was detected (not shown). In contrast, a mixture of C3b and factor B resulted in a substantial increase in signal to ∼25 RUs, or several times the sum of each component alone. This is best explained by the formation of a C3bBP complex on the biosensor surface. The mixture of C3b, factor B, and factor D together led to much greater signal (200 RUs), which was sensitive to factor H and DAF (Fig. 2B), and thus identified as C3bBbP. These results can be explained by two different mechanisms. 1) C3bB and C3bBb were assembling in the fluid phase prior to their association with properdin on the biosensor surface, and 2) C3b associated with the surface-bound properdin and the resulting C3bP intermediates provided sites for in situ C3bBP and C3bBbP assembly. Experiments were performed to determine whether surface-bound properdin can provide new sites for C3bBb formation. The properdin-coated biosensor was first treated with relatively high concentrations of C3b [50 μg/ml], and C3bP complexes were formed. This was quickly followed with either a factor B/factor D mixture or factor B alone. As seen in Fig. 3A, addition of a mixture of factor B and factor D to C3bP results in a complex with greater stability than C3bP that is sensitive to DAF (C3bBbP). Addition of factor B alone to the C3bP complexes (Fig. 3B) results in a complex that is resistant to DAF (C3bBP). These experiments demonstrate the in situ assembly of C3bBbP from C3bP and C3bBP intermediates on the properdin-coated biosensor surface. Experiments were next designed to determine whether preformed convertase would bind to the properdin-coated biosensor surface. The strategy was to allow C3bBb to form prior to injection and then block assembly of new C3bBb thereafter with the anti-human factor B mAb 14-III-03. This mAb is a mouse anti-human factor B that inhibits the assembly of human C3bBb (18Hourcade D.E. Wagner L.M. Oglesby T.J. J. Biol. Chem. 1995; 270: 19716-19722Abstract Full Text Full Text PDF PubMed Scopus (62) Google Scholar). It does not affect preformed C3bBb because it binds to the Ba portion of factor B, a region released during C3bBb formation. Thus, in one case C3b, factor B, and factor D were preincubated together in Mg2+-HEPES buffer for 3 min to allow for C3bBb assembly and treated with anti-Ba mAb just prior to injection into the biosensor. In a second case, factor B was first treated in buffer with mAb for 3 min, and C3b and factor D were added to the mixture just prior to injection. In the third case, C3b, factor B and factor D were mixed together in buffer and preincubated for 3 min prior to injection (no mAb). It takes ∼2 additional min for the mixtures to reach the flow cells after injection. The results (Fig. 4) show that anti-Ba mAb of factor B treatment prior to the preincubation period suppresses the formation of properdin C3bBb complexes. However, after the 3-min incubation, anti-Ba treatment does not suppress the formation of C3bBb-properdin complexes. This experiment demonstrated that preformed fluid phase C3bBb binds surface-bound properdin. Interactions of AP Proteins with iC3b-coated Biosensor Surfaces—I wished to test whether a single properdin protein could first bind to a surface ligand via one active site and then promote the assembly of C3bBb at an adjacent subunit. Properdin is also known to bind iC3b (19Lambris J.D. Alsenz J. Schultz T.F. Dierich M.P. Biochem. J. 1984; 217: 323-326Crossref PubMed Scopus (17) Google Scholar), a fragment generated from C3b through cleavage by factor I in the presence of cofactors MCP or factor H. Unlike C3b, iC3b is unable to directly participate in convertase formation with factor B and factor D. Thus, if the C3bBb complex were assembled on an iC3bP-coated surface, it would by necessity be assembled by virtue of a direct association with properdin, not iC3b. A biosensor surface was coated with iC3b, another with iC3b subsequently bound non-covalently with properdin (t1/2 of 30 min), and a third surface was coated with C3b. Complement components were injected simultaneously over these three surfaces and the control surface (Fig. 5). When factor B and factor D were added together, as expected, a complex formed on the C3b-coated surface (20Harris C.L. Abbott R.J.M. Smith R.A. Morgan B.P. Lea S.M. J. Biol. Chem. 2005; 280: 2569-2578Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). The complex was shown to be C3bBb because it was sensitive to DAF. No complex was formed on the iC3b and the iC3bP coated biosensors, because neither carried the necessary C3b subunit. In contrast, when a mixture of C3b, factor B, and factor D was injected together, a complex was formed on the iC3bP surface. Again, the complex was determined to be C3bBb, as it was sensitive to DAF. A complex was not formed on the iC3b-coated surface, because properdin was not present. These experiments demonstrate that properdin bound to a surface by one ligand-binding site promotes convertase assembly at ligand-binding sites of adjoining subunits. Properdin is a positive regulator of the alternative pathway convertases. Its capacity to stabilize AP has been long known (12Fearon D.T. Austen K.F. J. Exp. Med. 1975; 142: 856-863Crossref PubMed Scopus (317) Google Scholar). In this report I used SPR technology to demonstrate that properdin can also accelerate convertase assembly by several mechanisms. 1) Properdin bound to C3b promotes subsequent association of C3b with factor B. 2) Properdin bound to a C3b-coated target surface through one subunit can provide, through its other subunits, receptors for nascent and bystander C3b, preformed C3bB, and preformed C3bBb. C3bP and C3bBP intermediates can then fully assemble to C3bBb in situ. 3) Properdin bound to an iC3b-coated target surface can provide receptor sites for C3bBb formation. Previous models have properdin bind to a pre-existing cluster of surface-bound C3b (15Farries T.C. Lachmann P.J. Harrison R.A. Biochem. J. 1988; 252: 47-54Crossref PubMed Scopus (56) Google Scholar). Our findings support a new model in which properdin first binds to a surface ligand (C3b, iC3b, C3bB, or C3bBb) via one of its subunits and then promotes the assembly of further C3bBb at the ligand-binding sites of its adjoining subunits (Fig. 6). The full stabilizing effect of properdin on C3bBb would be attained when properdin binds more than one ligand at a time, with some of those ligands (i.e. C3b) covalently attached to the surface. A lattice of properdin:ligand interactions supported by C3b- or iC3b-dependent covalent bonds to a surface scaffold is more strongly stabilized than each isolated C3bP interaction. Consistent with the model, although not directly supported by the experiments in this study, nascent C3b bound to a target via properdin might be advantageously positioned to form a covalent bond with the target surface. Using surface-bound C3b, I determined that factor B binds C3bP better than it binds C3b (Fig. 1). Using surface-bound properdin, I found that properdin binds C3bB and C3bBb better than it binds C3b (Fig. 2A). Two simple explanations could account for these observations. 1) The C3bBP and C3bBbP complexes are more stable than C3bP, C3bB, or C3bBb because in the trimolecular complexes, properdin binds directly with factor B and Bb in addition to C3b (21Farries T.C. Lachmann P.J. Harrison R.A. Biochem. J. 1988; 253: 667-675Crossref PubMed Scopus (27) Google Scholar), and 2) C3b may take on two different conformations, one conformation that binds both factor B and properdin with relatively high affinity and a second conformation that binds both proteins with relatively low affinity. By this view, association of properdin or factor B with C3b would partially stabilize its high affinity binding conformation, thus promoting association of C3bB with properdin or of C3bP with factor B. The results of this study have several other interesting implications. First, properdin is a potent complement activator that binds to surface ligands, creating new sites for C3bBb generation. This process is possible because the multiple properdin subunits work together. Although it is known that properdin binds to C3b and iC3b (19Lambris J.D. Alsenz J. Schultz T.F. Dierich M.P. Biochem. J. 1984; 217: 323-326Crossref PubMed Scopus (17) Google Scholar), products of an ongoing complement response, properdin is also known to bind sulfatides (sulfated glycosphingolipids (22Holt G.D. Pangburn M.K. Ginsburg V. J. Biol. Chem. 1990; 265: 2852-2855Abstract Full Text PDF PubMed Google Scholar)). These or other ligands could be the basis for the antibody-independent initiation of the AP on certain target surfaces (see Ref. 23Pillemer L. Blum L. Lepow I.H. Ross O.A. Todd E.W. Wardlaw A.C. Science. 1954; 120: 279-285Crossref PubMed Scopus (409) Google Scholar). Second, properdin could be useful in the immunotherapeutic targeting of complement activation to the surfaces of harmful agents. Thus, a bifunctional agent composed of a targeting element and a properdin sequence could bind a cell or viral surface site and activate complement at that site. Vuagnat et al. (24Vuagnat B.B. Mach J. Le Doussal J.M. Mol. Immunol. 2000; 37: 467-478Crossref PubMed Scopus (12) Google Scholar) demonstrate that a cell surface that expresses a transmembrane form of properdin can activate the AP. Their result suggests that a properdin-dependent targeting strategy may be feasible. Third, iC3b is a degradative product of C3b that interacts with complement receptor 3 (CR3) and complement receptor 4 (CR4) on macrophages during phagocytosis (25Berger M. Volanakis J.E. Frank M.M. The Human Complement System in Health and Disease. Marcel Dekker, Inc., New York1998: 285-308Crossref Google Scholar). Previously, it was thought that C activation ceased once C3b was converted to iC3b. The results presented here indicate that iC3b can have a continued role in complement activation, through its affinity for properdin. As with C3b, this activity would occur on a surface. This model would make the stability of surface-bound iC3b a critical parameter for complement activation/regulation. iC3b is degraded to C3dg and C3c by factor I in the presence of the regulator CR1. The resulting surface-bound C3dg fragments do not bind properdin and so cannot promote further complement activation. If iC3b is not processed to C3dg efficiently, the accumulation of iC3b on a cell surface could limit cell lifespan or contribute to pathogenesis. Recent reports demonstrate certain disease states including atypical hemolytic uremic syndrome (26Richards A. Buddles M.R. Donne R.L. Kaplan B.S. Kirk E. Venning M.C. Tielemans C.L. Goodship J.A. Goodship T.H.J. Am. J. Hum. Genet. 2001; 68: 485-490Abstract Full Text Full Text PDF PubMed Scopus (263) Google Scholar, 27Goodship T.H.J. Liszewski M.K. Kemp E.J. Richards A. Atkinson J.P. Trends Mol. Med. 2004; 10: 226-231Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar, 28Zipfel P.F. Skerka C. Caprioli J. Manuelian T. Neumann H.H. Noris M. Remuzzi G. Int. Immunopharmacol. 2001; 1: 461-468Crossref PubMed Scopus (21) Google Scholar) and age-related macular degeneration (29Klein R.J. Zeiss C. Chew E.Y. Tsai J.Y. Sackler R.S. Haynes C. Henning A.K. Sangiovanni J.P. Mane S.M. Mayne S.T. Bracken M.B. Ferris F.L. Ott J. Barnstable C. Hoh J. Science. 2005; 308: 385-389Crossref PubMed Scopus (3570) Google Scholar, 30Edwards A.O. Ritter III, R. Abel K.J. Manning A. Panhuysen C. Farrer L.A. Science. 2005; 308: 421-424Crossref PubMed Scopus (2100) Google Scholar, 31Haines J.L. Hauser M.A. Schmidt S. Scott W.K. Olson L.M. Gallins P. Spencer K.L. Kwan S.Y. Noureddine M. Gilbert J.R. Schnetz-Boutaud N. Agarwal A. Postel E.A. Pericak-Vance M.A. Science. 2005; 308: 419-421Crossref PubMed Scopus (2091) Google Scholar) are associated with genetic defects in regulators of the AP. The role of properdin and its ligands in these and other cases should be reevaluated. In summary, I used SPR to examine properdin interactions with C3b and factor B. I demonstrated that properdin accelerates the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a C3b- or iC3b-coated surface. I presented a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, employs its unoccupied binding sites on its remaining subunits as receptors for nascent C3b, bystander C3b, or preformed C3bB and C3bBb complexes. The new C3bP and C3bBP act as intermediates in the generation of C3bBbP. Thus, properdin amplifies complement AP activation on a target surface through an organized assembly process. I am especially grateful to John Atkinson for his steadfast enthusiasm for properdin. His interest was a major determinant in the initiation of these studies. I also thank Feng Lin for DAF, John Atkinson for a critical reading of the manuscript, and Madonna Bogacki for help in preparing the manuscript." @default.
• W1983115827 created "2016-06-24" @default.
• W1983115827 creator A5070324321 @default.
• W1983115827 date "2006-01-01" @default.
• W1983115827 modified "2023-10-12" @default.
• W1983115827 title "The Role of Properdin in the Assembly of the Alternative Pathway C3 Convertases of Complement" @default.
• W1983115827 cites W1253835855 @default.
• W1983115827 cites W1522400689 @default.
• W1983115827 cites W1554698729 @default.
• W1983115827 cites W1558764429 @default.
• W1983115827 cites W1561282483 @default.
• W1983115827 cites W1603707847 @default.
• W1983115827 cites W1965855950 @default.
• W1983115827 cites W1970287941 @default.
• W1983115827 cites W1975908451 @default.
• W1983115827 cites W1977837863 @default.
• W1983115827 cites W1997888721 @default.
• W1983115827 cites W2009307992 @default.
• W1983115827 cites W2014513484 @default.
• W1983115827 cites W2041501170 @default.
• W1983115827 cites W2043018978 @default.
• W1983115827 cites W2058439079 @default.
• W1983115827 cites W2064497027 @default.
• W1983115827 cites W2086270622 @default.
• W1983115827 cites W2089439981 @default.
• W1983115827 cites W2113784410 @default.
• W1983115827 cites W2117386992 @default.
• W1983115827 cites W2157524529 @default.
• W1983115827 cites W2169194436 @default.
• W1983115827 cites W2335827761 @default.
• W1983115827 cites W2336152829 @default.
• W1983115827 cites W2411881901 @default.
• W1983115827 cites W3145351529 @default.
• W1983115827 doi "https://doi.org/10.1074/jbc.m508928200" @default.
• W1983115827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16301317" @default.
• W1983115827 hasPublicationYear "2006" @default.
• W1983115827 type Work @default.
• W1983115827 sameAs 1983115827 @default.
• W1983115827 citedByCount "202" @default.
• W1983115827 countsByYear W19831158272012 @default.
• W1983115827 countsByYear W19831158272013 @default.
• W1983115827 countsByYear W19831158272014 @default.
• W1983115827 countsByYear W19831158272015 @default.
• W1983115827 countsByYear W19831158272016 @default.
• W1983115827 countsByYear W19831158272017 @default.
• W1983115827 countsByYear W19831158272018 @default.
• W1983115827 countsByYear W19831158272019 @default.
• W1983115827 countsByYear W19831158272020 @default.
• W1983115827 countsByYear W19831158272021 @default.
• W1983115827 countsByYear W19831158272022 @default.
• W1983115827 countsByYear W19831158272023 @default.
• W1983115827 crossrefType "journal-article" @default.
• W1983115827 hasAuthorship W1983115827A5070324321 @default.
• W1983115827 hasBestOaLocation W19831158271 @default.
• W1983115827 hasConcept C104317684 @default.
• W1983115827 hasConcept C111684460 @default.
• W1983115827 hasConcept C112313634 @default.
• W1983115827 hasConcept C127716648 @default.
• W1983115827 hasConcept C159654299 @default.
• W1983115827 hasConcept C185592680 @default.
• W1983115827 hasConcept C188082640 @default.
• W1983115827 hasConcept C189446657 @default.
• W1983115827 hasConcept C203014093 @default.
• W1983115827 hasConcept C55493867 @default.
• W1983115827 hasConcept C7407320 @default.
• W1983115827 hasConcept C86803240 @default.
• W1983115827 hasConceptScore W1983115827C104317684 @default.
• W1983115827 hasConceptScore W1983115827C111684460 @default.
• W1983115827 hasConceptScore W1983115827C112313634 @default.
• W1983115827 hasConceptScore W1983115827C127716648 @default.
• W1983115827 hasConceptScore W1983115827C159654299 @default.
• W1983115827 hasConceptScore W1983115827C185592680 @default.
• W1983115827 hasConceptScore W1983115827C188082640 @default.
• W1983115827 hasConceptScore W1983115827C189446657 @default.
• W1983115827 hasConceptScore W1983115827C203014093 @default.
• W1983115827 hasConceptScore W1983115827C55493867 @default.
• W1983115827 hasConceptScore W1983115827C7407320 @default.
• W1983115827 hasConceptScore W1983115827C86803240 @default.
• W1983115827 hasIssue "4" @default.
• W1983115827 hasLocation W19831158271 @default.
• W1983115827 hasOpenAccess W1983115827 @default.
• W1983115827 hasPrimaryLocation W19831158271 @default.
• W1983115827 hasRelatedWork W138663713 @default.
• W1983115827 hasRelatedWork W1846297186 @default.
• W1983115827 hasRelatedWork W1986714262 @default.
• W1983115827 hasRelatedWork W2035494890 @default.
• W1983115827 hasRelatedWork W2059998763 @default.
• W1983115827 hasRelatedWork W2079993294 @default.
• W1983115827 hasRelatedWork W2103722562 @default.
• W1983115827 hasRelatedWork W2405540997 @default.
• W1983115827 hasRelatedWork W24736017 @default.
• W1983115827 hasRelatedWork W3124299845 @default.
• W1983115827 hasVolume "281" @default.
• W1983115827 isParatext "false" @default.
• W1983115827 isRetracted "false" @default.
• W1983115827 magId "1983115827" @default.
• W1983115827 workType "article" @default.